Table 5.
Combined immune response (detection of SARS-CoV-2 S1-IgG and/or IFN-y response) to vaccination in immunocompromised patients and healthy adults.
| Underlying disease | S1-IgG negative AND IGRA* negative or invalidn(%) | IGRA* positive, S1-IgG negativen(%) | S1-IgG positive, IGRA* negative or invalidn(%) | IGRA* and S1-IgG positiven(%) | IGRA* invalidn(%) |
|---|---|---|---|---|---|
| Lung transplant (n = 33) | 29 (87,9) | 1 (3.0) | 2 (6.0) | 1 (3.0) | 8 (24.2) |
| Kidney transplant (n = 24) | 14 (58.3) | 3 (12.5) | 5 (20.8) | 2 (8.3) | 9 (37.5) |
| Haemato-oncological (n = 24) | 12 (50) | 6 (25.0) | 2 (8.3) | 4 (16.6) | 3 (12.5) |
| Stem cell transplant (n = 19) | 3 (15.8) | 3 (15.8) | 6 (31.6) | 7 (36.8) | 3 (15.8) |
| Autoimmune disorder (n = 35) | 7 (20.0) | 14 (40.0) | 4 (11.4) | 10 (28.6) | 2 (5.7) |
| Variable immunodeficiency (n = 14) | 6 (42.9) | 1 (7.1) | 1 (7.1) | 6 (42.8) | 0 |
| HCW BNT162b2 (n = 38) | 0 | 0 | 0 | 38 (100) | 0 |
| HCW AZD1222/mRNA1273 (n = 27) | 0 | 0 | 0 | 27 (100) | 0 |
⁎
IGRA = Interferon Gamma Release Assay.